Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
Background The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between VTD and velcade, VRD induction regimens in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM).Methods This sy...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2025.2462249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825208864596819968 |
|---|---|
| author | Yin-Che Wang Cheng-Hsien Lin Yu-Chen Su Chieh-Lin Jerry Teng |
| author_facet | Yin-Che Wang Cheng-Hsien Lin Yu-Chen Su Chieh-Lin Jerry Teng |
| author_sort | Yin-Che Wang |
| collection | DOAJ |
| description | Background The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between VTD and velcade, VRD induction regimens in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM).Methods This systematic review and meta-analysis included 15 studies: six evaluating the VTD regimen and nine evaluating the VRD one. The primary endpoints were response rates after induction therapy and the incidence of a need for autologous hematopoietic stem cell transplantion (auto-HSCT) between the groups. We also examined the occurrence of grade 3 or 4 hematological, infection, and thrombotic AEs in both groups.Results The VTD group showed an overall response rate (ORR) of 93%, while the VRD group had an ORR of 86%. The very good partial response (VGPR) rates were 61% in the VTD group and 60% in the VRD one. The auto-HSCT rate was higher in the VTD group, averaging 93% compared to 70% in the VRD one. The incidence of grade 3 or 4 hematological AEs was 31% for VTD and 33% for VRD. The rates of grade 3 or 4 infection-related AEs were 9% in the VTD group and 14% in the VRD one. The incidence of grade 3 or 4 thrombotic AEs was 4% for VTD and 3% for VRD.Conclusions With comparable safety profiles, VTD and VRD induction therapies are similarly effective for transplant-eligible NDMM, showing similar ORRs and VGPR rates. |
| format | Article |
| id | doaj-art-71b5547625d048a8b0554b05dd0ec5b9 |
| institution | Kabale University |
| issn | 1607-8454 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-71b5547625d048a8b0554b05dd0ec5b92025-02-06T17:17:59ZengTaylor & Francis GroupHematology1607-84542025-12-0130110.1080/16078454.2025.2462249Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysisYin-Che Wang0Cheng-Hsien Lin1Yu-Chen Su2Chieh-Lin Jerry Teng3Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, TaiwanDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, TaiwanDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, TaiwanDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, TaiwanBackground The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between VTD and velcade, VRD induction regimens in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM).Methods This systematic review and meta-analysis included 15 studies: six evaluating the VTD regimen and nine evaluating the VRD one. The primary endpoints were response rates after induction therapy and the incidence of a need for autologous hematopoietic stem cell transplantion (auto-HSCT) between the groups. We also examined the occurrence of grade 3 or 4 hematological, infection, and thrombotic AEs in both groups.Results The VTD group showed an overall response rate (ORR) of 93%, while the VRD group had an ORR of 86%. The very good partial response (VGPR) rates were 61% in the VTD group and 60% in the VRD one. The auto-HSCT rate was higher in the VTD group, averaging 93% compared to 70% in the VRD one. The incidence of grade 3 or 4 hematological AEs was 31% for VTD and 33% for VRD. The rates of grade 3 or 4 infection-related AEs were 9% in the VTD group and 14% in the VRD one. The incidence of grade 3 or 4 thrombotic AEs was 4% for VTD and 3% for VRD.Conclusions With comparable safety profiles, VTD and VRD induction therapies are similarly effective for transplant-eligible NDMM, showing similar ORRs and VGPR rates.https://www.tandfonline.com/doi/10.1080/16078454.2025.2462249VTDVRDresponse rateprogression-free survivaladverse events |
| spellingShingle | Yin-Che Wang Cheng-Hsien Lin Yu-Chen Su Chieh-Lin Jerry Teng Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis Hematology VTD VRD response rate progression-free survival adverse events |
| title | Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis |
| title_full | Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis |
| title_fullStr | Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis |
| title_full_unstemmed | Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis |
| title_short | Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis |
| title_sort | bortezomib thalidomide and dexamethasone versus bortezomib lenalidomide and dexamethasone in transplant eligible newly diagnosed multiple myeloma a systemic review and meta analysis |
| topic | VTD VRD response rate progression-free survival adverse events |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2025.2462249 |
| work_keys_str_mv | AT yinchewang bortezomibthalidomideanddexamethasoneversusbortezomiblenalidomideanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaasystemicreviewandmetaanalysis AT chenghsienlin bortezomibthalidomideanddexamethasoneversusbortezomiblenalidomideanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaasystemicreviewandmetaanalysis AT yuchensu bortezomibthalidomideanddexamethasoneversusbortezomiblenalidomideanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaasystemicreviewandmetaanalysis AT chiehlinjerryteng bortezomibthalidomideanddexamethasoneversusbortezomiblenalidomideanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaasystemicreviewandmetaanalysis |